Stocksigma LogoStocksigma Logo

Concord Drugs Reports Strong Q2 FY27 Financial Results

Concord Drugs approved its un-audited financial results for the quarter and half-year ended 30th Sep'26

Concord Drugs Reports Strong Q2 FY27 Financial Results

Concord Drugs Ltd · Financial Result · 13 Nov 2026, 12:32 am

Concord Drugs Reports Strong Q2 FY27 Financial Results Concord Drugs approved its un-audited financial results for the quarter and half-year ended 30th Sep'26. On a consolidated basis, Q2 FY27 revenue from operations reached ₹2,080.95 lakhs compared to ₹1,027.85 lakhs in Q2 FY26. Consolidated net profit for the quarter rose sharply to ₹109.74 lakhs from ₹19.22 lakhs YoY, with basic and diluted EPS improving to ₹0.83 against ₹0.19 YoY. For H1 FY27, consolidated revenue stood at ₹4,175.65 lakhs and net profit reached ₹221.14 lakhs, outpacing share dilution effects.

Original exchange filing (PDF)

More announcements from Concord Drugs Ltd

All Concord Drugs Ltd announcements